Drug Profile
Aspirin/omeprazole 100/40
Alternative Names: Acetylsalicyclic acid/omeprazole 100/40; Omeprazole/acetylsalicyclic acid 40/100; Omeprazole/aspirin 40/100; PA-10040Latest Information Update: 28 Sep 2021
Price :
$50
*
At a glance
- Originator POZEN
- Developer Old API Wind-down Ltd
- Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiplatelets; Antipyretics; Antirheumatics; Antiulcers; Benzimidazoles; Cardiovascular therapies; Gastric antisecretories; Non-opioid analgesics; Salicylates; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide stimulants; Platelet aggregation inhibitors; Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Cardiovascular disorders; NSAID-induced ulcer
Most Recent Events
- 28 Sep 2021 No development reported - Preregistration for NSAID-induced ulcer (Prevention) in European Union (PO)
- 05 Jul 2019 Chemical structure information added
- 06 Feb 2019 Aralez Pharmaceuticals is now called Old API Wind-down